Alivus Life Sciences announced its unaudited financial results for the second quarter (Q2) and half-year (H1) ended September 30, 2025. The board approved these results in a meeting held on November 06, 2025. The company has reported revenue from operations of ₹5,879.80 million for the quarter. The results and auditor’s review report are available on the company’s website.
Financial Performance Overview
Alivus Life Sciences has released its unaudited financial results for the second quarter (Q2) and half-year ended September 30, 2025. The board of directors approved the results on November 6, 2025.
Key Financial Highlights
The following summarizes the key financial results for Q2 and H1 2025:
Revenue
Revenue from operations for the quarter stood at ₹5,879.80 million, compared to ₹5,068.79 million for the same quarter last year.
Net Profit
The company’s profit for the period after tax is reported at ₹1,300.26 million for the quarter ended September 30, 2025.
Earnings Per Share
Basic earnings per share for the quarter is ₹10.60.
Balance Sheet Highlights
Key figures from the balance sheet as of September 30, 2025:
Total Equity is reported at ₹30,153.56 million.
Total Assets amounted to ₹36,383.43 million.
Additional Information
The company has identified Active Pharmaceutical Ingredient (API) as its only operating segment.
As of September 30, 2025, there were 600,631 outstanding options under the Employee Stock Option Plan 2021, convertible into an equivalent number of equity shares.
Source: BSE
